Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.

Stachler MD, Camarda ND, Deitrick C, Kim A, Agoston AT, Odze RD, Hornick JL, Nag A, Thorner AR, Ducar M, Noffsinger A, Lash RH, Redston M, Carter SL, Davison JM, Bass AJ.

Gastroenterology. 2018 Jul;155(1):156-167. doi: 10.1053/j.gastro.2018.03.047. Epub 2018 Mar 31.

2.

Prevalence of Potentially Inappropriate Medication Use in Older Inpatients with and without Cognitive Impairment: A Systematic Review.

Redston MR, Hilmer SN, McLachlan AJ, Clough AJ, Gnjidic D.

J Alzheimers Dis. 2018;61(4):1639-1652. doi: 10.3233/JAD-170842.

PMID:
29278890
3.

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.

Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM.

Oncologist. 2017 Jan;22(1):107-114. doi: 10.1634/theoncologist.2016-0215. Epub 2016 Nov 7.

4.

Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.

Jessup CJ, Redston M, Tilton E, Reimann JD.

Hum Pathol. 2016 Mar;49:1-9. doi: 10.1016/j.humpath.2015.10.005. Epub 2015 Oct 31.

PMID:
26826402
5.

Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.

McIntire M, Redston M.

Arch Pathol Lab Med. 2012 May;136(5):496-503. doi: 10.5858/arpa.2011-0167-RA. Epub 2012 Jan 9. Review.

PMID:
22229849
6.

Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.

Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS.

J Clin Oncol. 2011 Aug 10;29(23):3153-62. doi: 10.1200/JCO.2010.33.0092. Epub 2011 Jul 11.

7.

Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors.

Cho NL, Carothers AM, Rizvi H, Hasson RM, Redston M, Bertagnolli MM.

J Surg Res. 2012 Apr;173(2):320-6. doi: 10.1016/j.jss.2010.10.037. Epub 2010 Nov 26.

PMID:
21195420
8.

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators.

Cancer Prev Res (Phila). 2009 Apr;2(4):310-21. doi: 10.1158/1940-6207.CAPR-08-0206. Epub 2009 Mar 31.

9.

p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.

Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M.

Clin Cancer Res. 2009 Mar 15;15(6):2116-22. doi: 10.1158/1078-0432.CCR-08-2674. Epub 2009 Mar 10.

10.

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M.

J Clin Oncol. 2009 Apr 10;27(11):1814-21. doi: 10.1200/JCO.2008.18.2071. Epub 2009 Mar 9.

11.

Aberrant crypt foci in the adenoma prevention with celecoxib trial.

Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2008 Jun;1(1):21-31. doi: 10.1158/1940-6207.CAPR-07-0011. Epub 2008 Apr 14.

12.

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS.

Clin Cancer Res. 2009 Jan 1;15(1):338-45. doi: 10.1158/1078-0432.CCR-08-1476.

13.

Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer.

Kimmelman AC, Hezel AF, Aguirre AJ, Zheng H, Paik JH, Ying H, Chu GC, Zhang JX, Sahin E, Yeo G, Ponugoti A, Nabioullin R, Deroo S, Yang S, Wang X, McGrath JP, Protopopova M, Ivanova E, Zhang J, Feng B, Tsao MS, Redston M, Protopopov A, Xiao Y, Futreal PA, Hahn WC, Klimstra DS, Chin L, DePinho RA.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19372-7. doi: 10.1073/pnas.0809966105. Epub 2008 Dec 2.

14.

Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome.

Sparr JA, Bandipalliam P, Redston MS, Syngal S.

Am J Surg Pathol. 2009 Feb;33(2):309-12. doi: 10.1097/PAS.0b013e3181882c3d.

15.

DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.

Bracht LK, Wen P, Meyerhardt JA, Kulke MH, Hornick JL, Redston M, LaFrankie DC, Black PM, Kesari S, Norden A, Drappatz J.

J Clin Oncol. 2008 Oct 10;26(29):4843-4. doi: 10.1200/JCO.2008.18.1776. Epub 2008 Sep 8. No abstract available.

PMID:
18779600
16.

Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk.

Cleary SP, Kim H, Croitoru ME, Redston M, Knight JA, Gallinger S, Gryfe R.

Dis Colon Rectum. 2008 Oct;51(10):1467-73; discussion 1473-4. doi: 10.1007/s10350-008-9356-7. Epub 2008 Jul 10.

17.

Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia.

Singh RS, Grayson W, Redston M, Diwan AH, Warneke CL, McKee PH, Lev D, Lyle S, Calonje E, Lazar AJ.

Am J Surg Pathol. 2008 Jun;32(6):936-42.

PMID:
18551751
18.

A mouse to human search for plasma proteome changes associated with pancreatic tumor development.

Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM.

PLoS Med. 2008 Jun 10;5(6):e123. doi: 10.1371/journal.pmed.0050123.

19.

High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.

Liau SS, Rocha F, Matros E, Redston M, Whang E.

Cancer. 2008 Jul 15;113(2):302-14. doi: 10.1002/cncr.23560.

20.

Hyperplastic/serrated polyposis in inflammatory bowel disease: a case series of a previously undescribed entity.

Srivastava A, Redston M, Farraye FA, Yantiss RK, Odze RD.

Am J Surg Pathol. 2008 Feb;32(2):296-303. doi: 10.1097/PAS.0b013e318150d51b.

PMID:
18223333
21.

Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia.

Srivastava A, Odze RD, Lauwers GY, Redston M, Antonioli DA, Glickman JN.

Am J Surg Pathol. 2007 Nov;31(11):1733-41.

PMID:
18059231
22.

Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types.

Martin ES, Tonon G, Sinha R, Xiao Y, Feng B, Kimmelman AC, Protopopov A, Ivanova E, Brennan C, Montgomery K, Kucherlapati R, Bailey G, Redston M, Chin L, DePinho RA.

Cancer Res. 2007 Nov 15;67(22):10736-43.

23.

Filiform serrated adenomas: a clinicopathologic and immunophenotypic study of 18 cases.

Yantiss RK, Oh KY, Chen YT, Redston M, Odze RD.

Am J Surg Pathol. 2007 Aug;31(8):1238-45.

PMID:
17667549
24.

Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study.

Jenkins MA, Hayashi S, O'Shea AM, Burgart LJ, Smyrk TC, Shimizu D, Waring PM, Ruszkiewicz AR, Pollett AF, Redston M, Barker MA, Baron JA, Casey GR, Dowty JG, Giles GG, Limburg P, Newcomb P, Young JP, Walsh MD, Thibodeau SN, Lindor NM, Lemarchand L, Gallinger S, Haile RW, Potter JD, Hopper JL, Jass JR; Colon Cancer Family Registry.

Gastroenterology. 2007 Jul;133(1):48-56. Epub 2007 Apr 25.

25.

Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice.

Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM.

Cancer Res. 2007 Mar 1;67(5):2366-72.

26.

Celecoxib for the prevention of sporadic colorectal adenomas.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators.

N Engl J Med. 2006 Aug 31;355(9):873-84.

27.

Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor.

Carothers AM, Moran AE, Cho NL, Redston M, Bertagnolli MM.

Cancer Res. 2006 Jun 15;66(12):6432-8.

28.

Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.

Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, Hanahan D, Redston MS, Chin L, Depinho RA.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52. Epub 2006 Apr 3.

29.

Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001.

Redston M, Compton CC, Miedema BW, Niedzwiecki D, Dowell JM, Jewell SD, Fleshman JM, Bem J, Mayer RJ, Bertagnolli MM; Leukemia Group B Trial 80001.

J Clin Oncol. 2006 Feb 20;24(6):878-83. Epub 2006 Jan 17.

PMID:
16418493
30.

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG.

J Invest Dermatol. 2006 Jan;126(1):154-60.

31.

Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, Kloppel G, Lauwers GY, Longnecker DS, Luttges J, Maitra A, Offerhaus GJ, PĂ©rez-Gallego L, Redston M, Tuveson DA.

Cancer Res. 2006 Jan 1;66(1):95-106.

32.

Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility.

Carothers AM, Javid SH, Moran AE, Hunt DH, Redston M, Bertagnolli MM.

Exp Cell Res. 2006 Feb 15;312(4):387-400.

PMID:
16368433
33.

Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival.

Matros E, Bailey G, Clancy T, Zinner M, Ashley S, Whang E, Redston M.

Cancer. 2006 Feb 1;106(3):693-702.

34.

Tumor microsatellite instability in early onset gastric cancer.

Bacani J, Zwingerman R, Di Nicola N, Spencer S, Wegrynowski T, Mitchell K, Hay K, Redston M, Holowaty E, Huntsman D, Pollett A, Riddell R, Gallinger S.

J Mol Diagn. 2005 Oct;7(4):465-77.

35.

CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions.

Duxbury MS, Matros E, Clancy T, Bailey G, Doff M, Zinner MJ, Ashley SW, Maitra A, Redston M, Whang EE.

Ann Surg. 2005 Mar;241(3):491-6.

37.

Carnosol inhibits beta-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse.

Moran AE, Carothers AM, Weyant MJ, Redston M, Bertagnolli MM.

Cancer Res. 2005 Feb 1;65(3):1097-104.

38.

Basal cell carcinoma with matrical differentiation: a case study with analysis of beta-catenin.

Haskell HD, Haynes HA, McKee PH, Redston M, Granter SR, Lazar AJ.

J Cutan Pathol. 2005 Mar;32(3):245-50.

PMID:
15701088
39.

Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin.

Lazar AJ, Calonje E, Grayson W, Dei Tos AP, Mihm MC Jr, Redston M, McKee PH.

J Cutan Pathol. 2005 Feb;32(2):148-57.

PMID:
15606674
40.

Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF).

Lepourcelet M, Tou L, Cai L, Sawada J, Lazar AJ, Glickman JN, Williamson JA, Everett AD, Redston M, Fox EA, Nakatani Y, Shivdasani RA.

Development. 2005 Jan;132(2):415-27. Epub 2004 Dec 16.

41.

Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer.

Javid SH, Moran AE, Carothers AM, Redston M, Bertagnolli MM.

Carcinogenesis. 2005 Mar;26(3):587-95. Epub 2004 Dec 3.

PMID:
15579483
42.

Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases.

Haddad R, Ogilvie RT, Croitoru M, Muniz V, Gryfe R, Pollet A, Shanmugathasan P, Fitzgerald T, Law CH, Hanna SS, Jothy S, Redston M, Gallinger S, Smith AJ.

Ann Surg Oncol. 2004 Nov;11(11):977-82. Epub 2004 Oct 15.

PMID:
15525826
43.

Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk.

Croitoru ME, Cleary SP, Di Nicola N, Manno M, Selander T, Aronson M, Redston M, Cotterchio M, Knight J, Gryfe R, Gallinger S.

J Natl Cancer Inst. 2004 Nov 3;96(21):1631-4.

PMID:
15523092
44.

Sentinel node staging of resectable colon cancer: results of a multicenter study.

Bertagnolli M, Miedema B, Redston M, Dowell J, Niedzwiecki D, Fleshman J, Bem J, Mayer R, Zinner M, Compton C.

Ann Surg. 2004 Oct;240(4):624-8; discussion 628-30.

45.

alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.

Swallow CJ, Partridge EA, Macmillan JC, Tajirian T, DiGuglielmo GM, Hay K, Szweras M, Jahnen-Dechent W, Wrana JL, Redston M, Gallinger S, Dennis JW.

Cancer Res. 2004 Sep 15;64(18):6402-9.

46.

Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice.

Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM.

J Biol Chem. 2004 Oct 8;279(41):43261-72. Epub 2004 Aug 4.

47.

High-resolution characterization of the pancreatic adenocarcinoma genome.

Aguirre AJ, Brennan C, Bailey G, Sinha R, Feng B, Leo C, Zhang Y, Zhang J, Gans JD, Bardeesy N, Cauwels C, Cordon-Cardo C, Redston MS, DePinho RA, Chin L.

Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72.

48.

Successful treatment of cap polyposis with infliximab.

Bookman ID, Redston MS, Greenberg GR.

Gastroenterology. 2004 Jun;126(7):1868-71.

PMID:
15188181
49.

Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.

Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM.

J Thorac Cardiovasc Surg. 2004 Jun;127(6):1579-86.

50.

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA.

Genes Dev. 2003 Dec 15;17(24):3112-26. Epub 2003 Dec 17.

Supplemental Content

Loading ...
Support Center